Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,410,132
  • Shares Outstanding, K 91,035
  • Annual Sales, $ 753,200 K
  • Annual Income, $ -263,300 K
  • EBIT $ -102 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.93
  • Price/Sales 1.83
  • Price/Cash Flow N/A
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 65.01% ( -5.23%)
  • Historical Volatility 63.74%
  • IV Percentile 88%
  • IV Rank 74.46%
  • IV High 83.16% on 03/25/24
  • IV Low 12.10% on 06/03/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 117
  • Volume Avg (30-Day) 107
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 1,840
  • Open Int (30-Day) 2,935

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 6
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.07
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.72 +9.85%
on 11/20/24
22.92 -29.43%
on 10/30/24
-5.39 (-25.00%)
since 10/25/24
3-Month
14.72 +9.85%
on 11/20/24
29.30 -44.81%
on 09/18/24
-11.48 (-41.52%)
since 08/26/24
52-Week
14.72 +9.85%
on 11/20/24
29.30 -44.81%
on 09/18/24
-1.85 (-10.27%)
since 11/24/23

Most Recent Stories

More News
Myriad Genetics Expands Partnership with Illumina to Enhance Genomic Profiling for Cancer Detection

Myriad Genetics updates its agreement with Illumina, integrating GIS for broader cancer diagnostics using TruSightâ„¢ Oncology 500 v2.Quiver AI SummaryMyriad Genetics has announced an update to its agreement...

MYGN : 16.17 (+2.93%)
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

MYGN : 16.17 (+2.93%)
Myriad Genetics Launches Prequel® Prenatal Screen Available as Early as Eight Weeks into Pregnancy

Myriad Genetics' Prequel® Prenatal Screen now offers genetic testing at eight weeks of pregnancy, enhancing early decision-making for expectant parents.Quiver AI SummaryMyriad Genetics, Inc. has announced...

MYGN : 16.17 (+2.93%)
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

MYGN : 16.17 (+2.93%)
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

MYGN : 16.17 (+2.93%)
Myriad: Q3 Earnings Snapshot

Myriad: Q3 Earnings Snapshot

MYGN : 16.17 (+2.93%)
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

MYGN : 16.17 (+2.93%)
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

MYGN : 16.17 (+2.93%)
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

MYGN : 16.17 (+2.93%)
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

MYGN : 16.17 (+2.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 17.28
2nd Resistance Point 16.82
1st Resistance Point 16.49
Last Price 16.17
1st Support Level 15.70
2nd Support Level 15.24
3rd Support Level 14.91

See More

52-Week High 29.30
Fibonacci 61.8% 23.73
Fibonacci 50% 22.01
Fibonacci 38.2% 20.29
Last Price 16.17
52-Week Low 14.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar